BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death

BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death

Abstract Background Despite advances in treatment, patients with refractory colorectal cancer (CRC) still have poor long-term survival, so there is a need for more effective therapeutic options. Methods To evaluate the HDAC8 inhibition efficacy as a CRC treatment, we examined the effects of various...

Full description

Bibliographic Details
Main Authors: Huey-Jiun Ko, Shean-Jaw Chiou, Cheng-Yu Tsai, Joon-Khim Loh, Xin-Yi Lin, Thu-Ha Tran, Chia-Chung Hou, Tai-Shan Cheng, Jin-Mei Lai, Peter Mu-Hsin Chang, Feng-Sheng Wang, Chun-Li Su, Chi-Ying F. Huang, Yi-Ren Hong
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Cell Communication and Signaling
Subjects:
HDAC8 inhibitor
CRC
TMZ
MGMT
β-catenin
p53
Online Access:https://doi.org/10.1186/s12964-022-01007-x

Internet

https://doi.org/10.1186/s12964-022-01007-x

Similar Items